| Jun 14 |
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
|
| Jun 14 |
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
|
| Jun 11 |
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
|
| Jun 6 |
Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk
|
| Jun 3 |
Pfizer, Takeda say four-year data support Adcetris as Hodgkin lymphoma treatment
|
| Jun 3 |
Takeda and Pfizer report positive Phase III HD21 trial of ADCETRIS
|
| Jun 3 |
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
|
| Jun 3 |
Blackstone Is Considering the Sale of Alinamin Pharmaceutical, Sources Say
|
| Jun 1 |
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
|
| May 31 |
Takeda gets positive opinion from EU regulators for cTTP therapy
|
